October 2004 in “Australian Prescriber” This abstract reviews the management of polycystic ovary syndrome and highlights the potential benefits of lifestyle changes over metformin in reducing type 2 diabetes risk, yet reports no new clinical outcomes.
45 citations
,
July 2002 in “The Neurologist” This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.
June 2025 in “British Journal of Dermatology” This case report observed that multiple sclerosis treatments were associated with worsening alopecia in a woman, highlighting the importance of informing patients about this potential side effect.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” This review outlines strategies for preventing, identifying, and managing complications related to current MS therapies and reports no new clinical results, emphasizing the growing complexity in MS treatment regimens.
September 2013 in “Neurodegenerative disease management” This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.